United States et al., ex rel. Strom v. Johnson & Johnson et al., No. 3:05-cv-03004-CRB (N.D. Cal.)
Nov 04, 2013
OUTCOME: Settled
The qui tam case was brought in July 2005 by Joe Strom, a former Scios Area Manager. Both Defendants will pay $184 million to resolve civil allegations that they unlawfully promoted their cardiac drug ...Natrecor for unapproved uses. In addition, in 2011, Scios agreed to pay an $85 million criminal fine and to plead guilty to a misdemeanor charge of introducing misbranded Natrecor into interstate commerce.
Health care
McAllen Hospitals, L.P., d/b/a South Texas Health System,
Feb 01, 2013
OUTCOME: Settled
McAllen Hospitals, L.P., d/b/a South Texas Health System, a wholly owned subsidiary of Universal Health Services, Inc. entered into a Settlement Agreement pursuant to which it paid $27.5 million to res...olve claims (see Complaint) concerning violations of the Stark and Anti-kickback laws. McAllen Hospitals, L.P., d/b/a South Texas Health System owns and/or operates multiple health care facilities in McAllen, Texas, including McAllen Medical Center, McAllen Heart Hospital, Edinburg Regional Medical Center, and the South Texas Behavioral Health Center. The case was originally filed in 2005 by our client, Bruce Moilan Sr. He received a $5.5 million relator share, 20% percent of the $27.5 million qui tam settlement. To read the Department of Justice Press Release
Health care
United States et al., ex rel. Austin et al. v. Novartis Pharmaceuticals Corporation, No. 8:03-CV-1551-T-30-TGW (M.D. Fla.)
Sep 30, 2010
OUTCOME: Settled
For the third time in one month, the national whistleblower law firm of Nolan & Auerbach, P.A. announces another substantial whistleblower recovery on behalf of their clients. Collectively, the cases h...ave returned in excess of $1.3 billion to the US Treasury to reimburse America’s health care programs. Earlier this month, the firm represented two whistleblowers in a $600 million overall settlement with Allergan, Inc. and one whistleblower in the $300 million overall settlement with Forest Laboratories, Inc. and its subsidiary Forest Pharmaceuticals, Inc. Today marks the unsealing of its clients’ cases against pharmaceutical manufacturer Novartis Pharmaceuticals Corporation, which has agreed to pay $237.5 million to resolve civil allegations that it unlawfully promoted its drug Trileptal for unapproved uses and that it paid illegal kickbacks to physicians to induce them to prescribe other of the company’s drugs: Diovan, Exforge and Tekturna. In addition, the company has agreed to pay a $185 million criminal fine and to plead guilty to a misdemeanor charge of introducing misbranded drugs into interstate commerce. Nolan & Auerbach, P.A. represented three of the key whistleblowers in this case, which was brought under the qui tam, or whistleblower, provisions of the False Claims Act. This settlement also resolves two other qui tam actions raising similar allegations.
